A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown During the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial)

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Dec 23

PMID 38136275

Authors

Olivier Molinier

Camille Guguen

Marie Marcq

Anne-Laure Chene

Philippe Masson

Frederic Bigot

Fabrice Denis

Fabienne Empereur

Philippe Saulnier

Thierry Urban

Affiliations

Soon will be listed here.

Abstract

The consequences of the strict health restrictions during the first wave of COVID-19 on lung cancer (LC) patients are not known. This cohort study evaluated the impact of the initial lockdown on management of and long-term outcome in LC patients. This exposed-unexposed-type study included two evaluation periods of 6 months each in non-selected patients; one began on the first day of lockdown in 2020, and the other in 2019 during the same calendar period. Various indicators were compared: clinical profiles, management delays and overall survival beyond 2 years. A total of 816 patients from 7 public or private centers were enrolled. The clinical characteristics of the patients in 2020 did not differ from those in 2019, except that the population was older ( = 0.002) with more non-smokers ( = 0.006). Delays for pre-therapeutic medical management were generally reduced after the first imaging in 2020 (1.28 [1.1-1.49]). In the multivariate analysis, being part of the 2020 cohort was correlated with better prognosis (HR = 0.71 [0.5-0.84], < 0.001). The gain observed in 2020 mainly benefited non-smoking patients, along with ECOG PS 0-2 ( = 0.01), stage 4 ( = 0.003), squamous cell carcinoma ( = 0.03) and receiving systemic therapy ( = 0.03). In conclusion, the first lockdown did not exert any deleterious impact on LC patients.

Citing Articles

Delay in Cutaneous Squamous Cell Carcinoma Diagnosis Due to Interrupted Services Is Associated with Worse Prognoses and Modified Surgical Approaches.

Taccioli F, Blessent C, Paganelli A, Fagioli F, Chester J, Kaleci S Cancers (Basel). 2024; 16(8).

PMID: 38672551 PMC: 11048546. DOI: 10.3390/cancers16081469.

References

Blay J, Boucher S, Le Vu B, Cropet C, Chabaud S, Perol D . Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. ESMO Open. 2021; 6(3):100134. PMC: 8134718. DOI: 10.1016/j.esmoop.2021.100134. View

Kasymjanova G, Anwar A, Cohen V, Sultanem K, Pepe C, Sakr L . The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. Curr Oncol. 2021; 28(6):4247-4255. PMC: 8544580. DOI: 10.3390/curroncol28060360. View

Kanarek N, Hooker C, Mathieu L, Tsai H, Rudin C, Herman J . Survival after community diagnosis of early-stage non-small cell lung cancer. Am J Med. 2014; 127(5):443-9. PMC: 4601577. DOI: 10.1016/j.amjmed.2013.12.023. View

Coughlin S, Plourde M, Guidolin K, Fortin D, Frechette E, Malthaner R . Is it safe to wait? The effect of surgical wait time on survival in patients with non-small cell lung cancer. Can J Surg. 2015; 58(6):414-8. PMC: 4651694. DOI: 10.1503/cjs.007015. View

Greenwood E, Swanton C . Consequences of COVID-19 for cancer care - a CRUK perspective. Nat Rev Clin Oncol. 2020; 18(1):3-4. PMC: 7582444. DOI: 10.1038/s41571-020-00446-0. View

Ward Z, Walbaum M, Walbaum B, Guzman M, de la Jara J, Nervi B . Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis. Lancet Oncol. 2021; 22(10):1427-1437. PMC: 8415898. DOI: 10.1016/S1470-2045(21)00426-5. View

Mayne N, Bajaj S, Powell J, Elser H, Civiello B, Fintelmann F . Extended Delay to Treatment for Stage III-IV Non-Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic. Clin Lung Cancer. 2022; 23(6):e362-e376. PMC: 9068243. DOI: 10.1016/j.cllc.2022.05.001. View

Dingemans A, Soo R, Jazieh A, Rice S, Kim Y, Teo L . Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic. J Thorac Oncol. 2020; 15(7):1119-1136. PMC: 7227539. DOI: 10.1016/j.jtho.2020.05.001. View

Rosenbaum L . The Untold Toll - The Pandemic's Effects on Patients without Covid-19. N Engl J Med. 2020; 382(24):2368-2371. DOI: 10.1056/NEJMms2009984. View

10.

Priou S, Lame G, Zalcman G, Wislez M, Bey R, Chatellier G . Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort study. Eur J Cancer. 2022; 173:33-40. PMC: 9234022. DOI: 10.1016/j.ejca.2022.06.018. View

11.

Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N . Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies. Lancet Reg Health Eur. 2022; 22:100492. PMC: 9445429. DOI: 10.1016/j.lanepe.2022.100492. View

12.

Arrieta O, Lara-Mejia L, Bautista-Gonzalez E, Heredia D, Turcott J, Barron F . Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies. Oncologist. 2021; 26(12):1035-1043. PMC: 8649017. DOI: 10.1002/onco.13962. View

13.

Singh A, Berman A, Marmarelis M, Haas A, Feigenberg S, Braun J . Management of Lung Cancer During the COVID-19 Pandemic. JCO Oncol Pract. 2020; 16(9):579-586. DOI: 10.1200/OP.20.00286. View

14.

Samson P, Patel A, Garrett T, Crabtree T, Kreisel D, Krupnick A . Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2015; 99(6):1906-12. PMC: 4458152. DOI: 10.1016/j.athoracsur.2015.02.022. View

15.

Sud A, Jones M, Broggio J, Loveday C, Torr B, Garrett A . Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020; 31(8):1065-1074. PMC: 7237184. DOI: 10.1016/j.annonc.2020.05.009. View

16.

Bhalla S, Bakouny Z, Schmidt A, Labaki C, Steinharter J, Tremblay D . Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. Lung Cancer. 2021; 160:78-83. PMC: 8284065. DOI: 10.1016/j.lungcan.2021.07.002. View

17.

Vinod S, Chandra A, Berthelsen A, Descallar J . Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?. Lung Cancer. 2017; 112:16-24. DOI: 10.1016/j.lungcan.2017.07.032. View

18.

Girard N, Greillier L, Zalcman G, Cadranel J, Moro-Sibilot D, Mazieres J . Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. Respir Med Res. 2020; 78:100769. PMC: 7246014. DOI: 10.1016/j.resmer.2020.100769. View

19.

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R . The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020; 21(8):1023-1034. PMC: 7417808. DOI: 10.1016/S1470-2045(20)30388-0. View

20.

Cantini L, Mentrasti G, Russo G, Signorelli D, Pasello G, Rijavec E . Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open. 2022; 7(2):100406. PMC: 8810307. DOI: 10.1016/j.esmoop.2022.100406. View